Cognision, a provider of advanced neurobiomarker technology, on Friday announced a partnership with precision neuropsychiatry specialist Kynexis to use the COGNISION System in Kynexis' Phase 2 clinical trial of KYN-5356 in subjects with schizophrenia.

KYN-5356 is designed to inhibit KAT-II, an enzyme central to the kynurenine pathway implicated in cognitive impairment associated with schizophrenia (CIAS) -- a debilitating symptom for which no approved treatments currently exist. The ongoing Phase 2 study aims to establish proof of clinical concept for KYN-5356 by demonstrating its efficacy in improving cognitive performance.

Kynexis will use the COGNISION System to precisely measure drug-induced changes in brain function.